https://packagist.org/packages/sb15/dom
sb15/dom - Packagist.org
sb15dompackagist
https://packagist.org/packages/sb15/php-class-generator
sb15/php-class-generator - Packagist.org
php classsb15generatorpackagist
https://packagist.org/packages/sb15/phalcon-json-rpc-application
sb15/phalcon-json-rpc-application - Packagist.org
json rpcsb15phalconapplicationpackagist
https://packagist.org/packages/sb15/jsonrpc-bundle
sb15/jsonrpc-bundle - Packagist.org
sb15jsonrpcbundlepackagist
https://packagist.org/packages/sb15/legacy-library
sb15/legacy-library - Packagist.org
legacy librarysb15packagist
https://www.biospace.com/1-year-outcomes-of-phase-3-study-for-sb15-proposed-biosimilar-to-eylea-aflibercept-presented-at-the-2023-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at...
Apr 25, 2023 - Samsung Bioepis Co., Ltd. today announced that 1-year outcomes of the Phase 3 study for SB15, a proposed biosimilar to Eylea1(aflibercept), were presented at...